The aim of this study was to investigate the involvement of the transient receptor potential ankyrin 1 (TRPA1) in haemorrhagic cystitis, the main side effect of cyclophospha mide-based chem otherapy. Hannover female rats received intraperitoneal (i.p.) injecti on of cyclophospha mide (three doses of 100 mg/ kg, every other day, in a total of five days). This treatment was followed by the treatment with TRPA1 antag onist HC 030031 (50 mg/kg, p.o.). The threshold for hindpaw withdrawal or abdominal retraction to von Frey Hair and the locomotor activity were measured. The treatment with the TRPA1 antagonist HC 030031 significantly decreased mechanical hyperalgesia induced by cyclophosphamide without interfere with locomotor activity. Urodynamic parameters were performe d by cystometry 24 h after a single treatment with cyclophospha mide (200 mg/kg , i.p.) in control and HC 030031 treated rats. Analyses of the urodynamic parameters showed that a single dose of cyclophosphamide was enough to significantly increase the numbe r and amplitude of non-voiding contraction s and to decrease the voided volume and voiding efficiency, without significantly altering basal, threshold or maximum pressure. The treatment with HC 030031 either before (100 mg/kg, p.o.) or after (30 mg/kg , i.v.) cyclophosphamide inhibited the non-voiding contractions but failed to counteract the loss in voiding efficiency. Our data demonstrates that nociceptive symptoms and urinary bladder overactivity caused by cyclophosphamide, in part, are dependent upon the activation of TRPA1. In this context, the antag onism of the receptor may be an alternative to minimise the urotoxic symptoms caused by this chemotherapeutic agent.
Introduction
Cyclophospham ide is an alkylating agent that has long been used in the treatment of solid tumours, lymphom a, myeloma and chronic lymphocytic leukaemia. More recently, cyclophospham ide has been employed for the treatment of non-neoplastic diseases, including thrombocy topenic purpura, rheumatoid arthritis, systemic lupus erythematosus and as a conditioner before bone marrow transplanta tion [1] [2] [3] . Side effects for the treatment with cyclophospham ide were described by Coggins and co-workers as early as 1960 [4] . Among the side effects, the urologica l disturbances present the major limiting factor in its use. Effects vary from transient irritating voiding symptoms, such as urinary frequency, dysuria, urgency, suprapubic discomfort and strangury with microhae maturia, to life-threaten ing haemorrhagi c cystitis. Urinary bladder fibrosis, necrosis, contracture and vesicoureter al reflux were also associate d with cyclophosphami de therapy [4, 5] .
The urotoxicity of cyclophosphami de is not directly related to its alkylating activity but rather to the formatio n of hydroxylate d metaboli tes, particularly acrolein, which is formed from hepatic microsom al enzymatic hydroxylation for further renal excretion [6] . The storage of acrolein within the urinary bladder causes irritation of the urothelium resulting in inflammation that is characterised by urinary bladder hyperreflexia [7] . In addition, acrolein is reported to be the most reactive of the a,b-unsaturated aldehydes, and rapidly binds to and depletes cellular nucleophiles such as glutathione . Acrolein can also react with some proteins residues and nucleophilic sites in DNA. Of note, Bautista and collaborator s (2006) demonstrat ed that acrolein produced a robust increase in calcium influx that was selectively dependent on TRPA1 [8, 9] .
TRPA1 is a calcium-p ermeable nonselective ion channel with six transmemb rane domains and a unique ankyrin repeat in the amino terminal portion that contains cysteine residues that are sensitive to alkylation and activation [9, 10] . The cysteine residues are the targets for electrophili c compound s and so the receptor is sensitive to a broad range of naturally occurring compounds including: allyl isothiocyan ate; cinnamalde hyde; allicin; the environmental irritant acrolein; the volatile irritant formalin and the end-products of bacterial , inflammatory and oxidative stress hydrogen sulphide , hypochlorid e, hydrogen peroxide, 4-hydronon enal and 4-oxo-nonenal [11, 12] . TRPA1 is highly expresse d in unmyelinat ed and thinly myelinated sensory neurons [10, 13, 14] . The receptor was identified in neuronal and non-neuron al structure s of the lower urinary tract, including unmyelinated nerve fibres innervating the epithelial cells (urothelium), the suburothelial space, muscle layers and blood vessels of the rodent urinary bladder [13, 15] and in the human urethra [16] .
The role of TRPA1 in pathological processes of the lower urinary tract has been suggested because the receptor is overexpressed in urinary bladder mucosa of patients suffering outlet obstruction of this organ and in the urothelium and neurons innervati ng the urinary bladder of rats undergoing spinal cord injury [17, 18] . TRPA1 mediates the contractile response caused by allyl isothiocyan ate and cinnamalde hyde in the rat urinary bladder [19] and the intravesical administrat ion of TRPA1 agonists cause urinary bladder overactivity [15, 20] .
Taking into account the role of TRPA1 in the pathophysiol ogical processes of the lower urinary tract and its sensitivity to the cyclophosphamid e-metabolite acrolein, we hypothesised that antagonism of TRPA1 by a selective antagonist, HC 030031, would minimise the urotoxic symptoms caused by cyclophospham ide treatment and in turn, decrease the side effects of this chemoth erapeutic drug. Therefore, we evaluated the role of the TRPA1 antagonist HC 030031 in the urodynamic paramete rs and in the nociceptive responses in rats that were treated with cyclophospham ide.
Material and methods

Animals
Female Hannover rats weighing 150-250 g, age 6-7 weeks, were used. Animals were housed in cages (up to four per cage) in racks model ALERK-dg-50 (Alesco Ind. & Com. Ltda, São Paulo, Brazil) with ventilated control. The room was maintained at a constant temperature of 22 ± 2°C under a 12 h light/12 h dark cycle at 60-80% humidity with food and water available ad libitum . The rats were maintained together as long as they were born to ensure that they were under the same estrous cycle during the analyses. In our hands, cyclophosphami de presented broader toxicity to male than female and this caused a limitation to the experime ntal model in males. The experime ntal procedures were approved by the ethics committee of the Federal University of Santa Catarina (PP00607) and followed the National Institutes of Health Animal Care Guidelines (NIH Publicati ons N°80-23).
Treatmen t protocol
For behaviou ral assessment, rats (n = 6 per group) received three doses of 100 mg/kg cyclophosphami de via intraperi toneal (i.p.) on the first, third and fifth days (Diagram 1). This schedule of treatment allows the installati on of urinary cystitis before starting any therapeutic treatment and mediates a sub chronic inflammatory situation . This schedule of treatment was followed as described before for female rats [21] , with minor modifications. Twenty-fou r hours after the third injection , on the sixth day, rats received the first treatment with HC 030031 (50 mg/kg) by gavage (p.o.). Treatment with HC 030031 was repeated every twelve hours, with three doses of HC 030031 in total. The mechanical threshold and the locomotor activity were evaluated before the treatments (baseline) and after the first and third doses of HC 030031. The rats were not fed during behavioural tests.
To understand the mechanisms of cyclophosphami de-induced urotoxicity, the urodynamic parameters were taken twenty-four hours after a single dose of cyclophospham ide (200 mg/kg, i.p.) [22] . This acute treatment allows investigating earlier mechanisms of cyclophospham ide-induced urotoxicity. When investiga ting the effects of the TRPA1 receptor antagonist, reproduci ble micturition cycles were recorded before (used as baseline values) and during 45 min following administ ration of HC 030031 (30 mg/kg, 0.1 ml/ min for 10 min) or vehicle (8% DMSO + 2% Tween 80 in saline), intravenousl y (i.v., caudal vein) (Diagram 2A). The administrat ion of HC 030031 24 h after cyclopho sphamide intended to evaluate the role of TRPA1 receptor after installati on of haemorrhagi c cystitis. The dose of the antagonist was selected on the basis of previous studies and this percentage of DMSO has not altered cystometric paramete rs [17] . To evaluate whether the antagonism of TRPA1 would display some preventive effect against haemorr hagic cystitis, another scheme of treatment was performed by treating rats with HC 030031 (100 mg/kg, p.o.) one hour before cyclopho sphamide (Diagram 2B). The groups (n = 6 rats per group) were divided in naïve; cyclophosphami de (200 mg/kg, i.p.); HC 030031 (100 mg/kg, p.o.) one hour before cyclopho sphamide (200 mg/kg, i.p.); HC 030031 (30 mg/kg, i.v.) 24 h after cyclopho sphamide (200 mg/kg, i.p.).
Both behavioural and urodymic analysis were performed in a double-blind ed scheme for the treatment and measure ments.
Mechanical hyperalge sia
The mechanical hyperalgesia induced by the i.p. injection of cyclophospham ide was evaluated through the application of von Frey Hair to the rat hindpaw and abdomin al cavity, according to the method previously described [23, 24] , with some modifications. Rats were individually placed in clear Plexiglas boxes (13.8 cm Â 18.0 cm Â 68.2 cm) on an elevated wire-mes h platform (23.0 cm Â 39.8 cm Â 72.7 cm) to allow access to the abdominal and plantar surface of both hindpaws. The animals were acclimatised for at least 1 h prior to the behaviou ral test. The withdrawal response was quantified by means of the electronic pressure-mete r test for rats, which consisted of a hand-held force transducer fitted with a 0.7 mm 2 polypropylene tip (electronic von Frey anesthesiometer, IITC Inc., Life Science Instruments , USA). The stimulus was applied on the plantar surface of the left hindpaw and on the lower abdominal cavity. The intensity of the stimulus (g) was automatical ly recorded when the paw was withdraw n or when the abdomen was retracted. The stimulus was applied three times alternatel y and the mean of these values was registered as the mean force supported by the rat. The nociceptive responses were evaluated at different time-poi nts following cystitis induction. All groups were evaluated before cyclophospham ide injection in order to determine the baseline mechanical thresholds.
Locomotor activity
The locomotor performanc e was scored, evaluating the number of crossings and rearings by the open-field test. For this purpose, rats were separated in four groups: vehicle, cyclophosphami de, HC 030031, cyclophosphami de plus HC 030031, as described in the treatment protocol, and placed in the centre of a round openfield (50 Â 98 Â 80 cm), in which the floor was divided into 12 areas. The number of areas crossed and the rearing responses was recorded for 5 min.
Cystometri c parameters
For the urodynamic studies, rats were anaesthe tised with urethane (1.1 g/kg, i.p.). A PE-60 polyethylene catheter (Clay Adams, Parsippa ny, NJ, USA) was inserted via a midline abdominal incision into the bladder through its dome. The intravesical catheter was connected via a three-way stopcock to a pressure transducer (ADInstruments Pty Ltd., Castle Hill, Australia ) and to a microinfusion pump (Insight Equipamentos Científicos, Ribeirão Preto, SP, Brazil) for recording intravesical pressure and infusing saline into the bladder, respectively . Intravesical pressure was continuously recorded using data acquisition software (PowerLab 8/30, ADInstruments ). After catheter implantation, rats were left undisturbed for the next 30 min for bladder stabilisation. After this period, saline at 37 °C was infused at a rate of 0.1 ml/min.
We assessed the micturiti on pressure (MP, maximum bladder pressure during micturition), basal pressure (BP, the lowest bladder pressure between micturitions), and threshold pressure (TP, bladder pressure immediately before micturition). The number and mean amplitude of non-voiding contraction s (NVCs) were also measured. Non-voiding contractions were defined as a rhythmic intravesical pressure increase greater than 5 mmHg from baseline pressure without release of saline from the urethra.
The volume of voided saline from urethral meatus was collected and measured to determine voided volume [25] . In order to measure residual volume, the saline infusion was stopped at the beginning of the voiding contraction, and the residual volume (RV) was measure d by harvesting saline through the intravesical catheter and then manually expressing the remaining intravesical contents by exerting pressure on the bladder abdominal wall. The bladder capacity (BC) was calculated as the voided volume plus the residual volume, and the voiding efficiency (VE) was determined as a percentage using the following equation: VE = [(VV/BC) Â 100]. The cystomet ric parameters were calculated from voiding cycles obtained during 45 min.
Statistica l analysis
Results are presented as mean ± S.E.M of six animals. Data were analysed by one or two-way analyses of variance (ANOVA) followed by Newman-Keuls test when appropriate. P values less than 0.05 (P < 0.05) were indicative of significance.
Results
The systemic treatment with cyclophosphami de caused a persistent hyperalgesia as evidenced by a decrease in withdraw al response threshold to von Frey Hair stimuli [F (4; 16) = 6.929; P < 0.002]. There was a similar response when the stimulus was applied on the abdominal area or on the hindpaw surface [F (4; 16) = 1.278; P > 0.05] (Fig. 1A ). This suggests that cyclopho sphamide induces a referred hyperalgesi a and we chose the hindpaw area to perform the next experiments as it offers a more reliable method for evaluating withdrawal response. Cyclophospham ide induced a consistent and reproducibl e hyperalgesia from one to six hours; hence we assumed that this scheme of treatment was consistent with the progress of urinary bladder cystitis. Once urinary bladder cystitis had been installed, the treatment with TRPA1 antagoni st HC 030031 (50 mg/kg, p.o.) was started. After the third dose of HC 030031 (second day of treatment) there was a mild but significant reduction of hyperalgesi a. The anti-hyperal gesic effect was significant only one hour after HC 030031 treatment (Fig. 1B) .
Rats treated with cyclopho sphamide also presented locomotor alterations, which were likely related to the abdomin al discomfort caused by cystitis ( Fig. 1C and D) . As a result, we detected a significant decrease in the numbers of crossing [F (1; 24) = 14.314; P < 0.05] and rearing [F (1; 24) = 17.588; P < 0.05] in rats that received cyclopho sphamide. The treatment with three doses of HC 030031 in healthy rats did not alter either crossing [F (1; 24) = 0.026; P > 0.05] or rearing [F (1; 24) = 0.078; P > 0.05] numbers, showing that HC 030031 did not cause any sedative effect at this schedule of treatment. In addition, HC 030031 did not significantly attenuate the reduction in locomotor activity caused by cyclophospham ide. No significant interactions were detected for the combined treatment in crossing [F (1; 24) = 0.779; P > 0.05] and rearing [F (1; 24) = 0.128; P > 0.05] tests ( Fig. 1C and D) .
The urotoxic effect of cyclopho sphamide was confirmed through cystometric analyses. The histogram at the Fig. 2A and B illustrates the number of the non-voiding contraction s (NVCs) and the amplitude of these NVCs contractions. The NVCs were defined as the rhythmic intravesical pressure greater than 5 mmHg from baseline pressure, without the release of saline from the urethra. The NVCs are identified by the continuous arrows over the peaks (Fig. 2F and G) . Naive rats did not show any NVCs during the bladder-filling phase and each peak at the trace represents a micturition (Fig. 2C, dotted arrow) . Oppositely to the naïve rats, the treatment with cyclophospham ide induced a marked number of NVCs, with high amplitud e in these contraction s, indicating spontaneou s detrusor overactivi ty (Fig. 2F) . Treatment with cyclophosphamid e induced polymorphi c micturition cycles with improper storage and voiding phase leading to bladder distension. Interesting, the systemic pre-treatment with HC 030031 (100 mg/kg, p.o.) decreased NVCs by 68.75 ± 1.3% (Fig. 2G) . Additionally, the post-treatmen t with HC 030031 (30 mg/kg, i.v.) completely abolished the NVCs induced by cyclopho sphamide (Fig. 2H) . The administrat ion of HC 030031 either by oral or intravenous route did not alter cystomet ric parameters by itself ( Fig. 2D and E).
Rats treated with cyclophospham ide also presente d a decrease d voided volume and voiding efficiency, achieving only 32 ± 2.9% and 13 ± 2.6% activity of the control, respectively (Fig. 3A and B) . The intravenous administ ration of HC 030031 partially recovered voided volume by 45 ± 2.3% and to a better degree the voiding efficiency, with 57 ± 8.8% activity of the healthy control (Fig. 3B) . The oral treatment with HC 030031 prevented neither voided volume nor voiding efficiency impairment. The cystometric analysis also revealed a slight increase in basal and threshold pressure and a slight decrease in maximum pressure; none of these alterations were significant. Both schedule s of HC 030031 treatment presente d similar profiles to that with the cyclophosphami de treated group (Fig. 4) .
Discussion
The urologica l symptom s caused by cyclophosphami de are well characteri sed side effects during chemotherape utic interventions [4,5,26,2 7] . In this context, acute or chronic treatments with cyclophosphami de have been widely used as models for haemorrhagic cystitis in rodents, either to identify the intracellular pathways involved in haemorrhagic cystitis or to search for new drugs to offset the pathologi cal state. Chronic administ ration of cyclopho sphamide causes abdominal mechanical hyperalgesia and urinary bladder overactivity in mice, as assessed by von Frey Hair application and cystometry [28] . Furthermore, acute and chronic treatment with cyclophospham ide causes bladder dysfunction in female rats [29] . In this study, we have extended these findings and demonstrated that treatment with cyclophosphami de induces mechanical hyperalges ia and overactivity of the urinary bladder in rats.
In a recent review, Geppetti and collaborators reported that cyclopho sphamide induces a neurogen ic inflammation in the lower urinary tract, suggesting that its metabolite, acrolein, directly activates TRPA1 receptors from sensory neurons. As a consequence, the activation of TRPA1 may be due to a secondary inflammation involving c-fos overexpress ion, release of inflammatory peptides and activation of a 1 -adrenergi c receptors [30] . Our findings demonstrate that the effects of cyclophosphami de/acrolein do not involve the synthesis of de novo TRPA1 because mRNA expression was similar in naive and cyclopho sphamide-trea ted groups (data not shown). However, these results do not exclude the possibilit y of post-trans lational changes in the immature form of the protein.
Acrolein, an important environm ental irritant present in tear gas and vehicle exhaust, also targets TRPA1 from pulmonary tissue [8] . In vivo , acrolein is formed in conjunction with phosphorami de mustard by hydroxylation of cyclophosphami de through hepatic microsomal enzymes [6, 31] . Furthermore, acrolein is able to rapidly enter the uroepithelium because of its chemical nature, where it causes its main toxic effect. In agreement with this, the direct intravesical injection of acrolein increased vascular bladder permeability and plasma exudatio n [32] .
The direct activation of TRPA1 by acrolein has been demonstrated in vitro [8] and this may be the main mechanism by which acrolein induces urotoxicity. However, taking into account the low concentratio n of acrolein in urine of patients undergoing cyclophosphamid e treatment, it may also cause urotoxicity by other mechanism s [33] . As reported by Korkmaz and collaborators, a disruption in the redox status of the cell, driven by cyclophosphamide/acrolei n, could be the main inducer of urotoxicity [5] . This fact is interesting because the cysteine residues containe d in the ankyrin sequence of TRPA1 are, in fact, sensors for the impairment of oxidation-reduction status of the cell. Therefore, TRPA1 may be a direct target for acrolein and also an indirect target for the oxidised substances generate d by acrolein accumulation. Of note, the disruption of redox status in the cell may affect other proteins and this nonspecific effect might also contribute to acrolein toxicity [34] .
In the present study, we show an involvement of TRPA1 in the urotoxic symptoms of cyclophospham ide treatment. The visceral inflammation and pain induced by cyclopho sphamide sensitizes a somatic area at the spinal cord which causes referred pain [24, 35, 36 ] . In accordance with this, rats treated with cyclophosphamide presented a similar sensitivity when the stimulus (von Frey Hair) was applied to either the abdominal area or to the ventral surface of the hindpaw .
The consecutive treatment with the TRPA1 antagonist HC 030031 partially decreased mechanical hyperalgesi a suggesting that TRPA1 is a putative target to countera ct symptoms related to urinary bladder cystitis. The neuronal inputs caused by the agonism of TRPA1 in pelvic nerves is an important mechanism to cause visceral pain and, therefore, the antagonism of TRPA1 has been suggested as a promisor therapy against somatic pain [37, 38] . TRPA1 activation is associate d with nerve growth fact (NGF) synthesis and phospho rylation of p38 [14] , a mechanis m that will maintain hyperalgesi a even in the absence of the initial stimulus . Of interest, NGF was overexpressed within bladder and in L 6 /S 1 dorsal root ganglia in acute and subacute cystitis induced by instillation of acrolein and the systemic treatment with NGFneutraliz ing antiserum or intravesical treatment with a trkA antagonist supressed mechanical hyperalgesia [35] . In fact, NGF has been described to contribute to urinary bladder hyperreflexia [39] [40] [41] [42] and somatic sensitivity [43] [44] [45] .
In addition, the treatment with cyclophosphami de induced an overexpress ion of interleukins : IL-1 b, IL-4, IL-18 and interfero n c [46] . This might contribute to a diffuse inflammatory response and activation of intracellular messengers. In fact, the treatment with cyclophospham ide induced urinary bladder hyperreflexia related to the activation of JAK-STAT pathway [21] , phosphoryla tion of Akt [29] and extracellul ar signal regulated kinase (ERK) [47, 48] . As a consequence of this inflammatory signaling, the synthesis of kinins, mast-der ived trypsin, fatty acids metaboli tes, chemoki nes, nitric oxide and nitrate derivative compounds will further sensitize TRPA1 [49] [50] [51] [52] [53] [54] [55] .
The urodynami c parameters have confirmed the capability of cyclopho sphamide to induce bladder overactivi ty. Overactiv e urinary bladder is a syndrome characterized by exacerbated contractions of the urinary bladder during the filling phase, associate with detrusor sphincter dyssynergi a and inefficient voiding [56, 57] . We found that a single acute treatment with cyclophospham ide significantly increased the number and amplitud e of non-void ing contraction s, decreased voided volume and voiding efficiency, but only slightly increased basal and threshold pressure. It is noteworthy that voiding efficiency is the ratio between the voided volume and the urinary bladder capacity, whereas the capacity is the total voided volume plus residual volume; therefore, a high number of non-voiding contractions in conjunction with a low voiding efficiency support an overactivity of the organ that is not associate d with micturiti on. This is a feature of the bladder dysfunct ion during cystitis. Of relevance, these urodynamic parameters are in agreement with previous findings that used acute treatment with cyclophosphami de to induce cystitis [21, 58] .
The non-voiding contractions are represented by increased spontaneou s activity of the detrusor smooth muscle cells during the filling phase, which may cause bladder overactivity. It has been shown that the spontaneou s phasic activity of the detrusor tissue is myogeni c in origin [59] and that the urotheliu m plays a significant role in modulating the nature of these contractions [60] . Additionally, the modulation of ion channels in sensory fibers and urothelial cells by mechanical stimuli and inflammatory cytokine s can lead to voiding disorders [61] . Recently , TRPA1 receptor expression has been described in both C fibers innervating urinary bladder and in urothelial cells, where it is suggested to act as mechano sensor and nociceptor in either physiological or pathologi cal states [15, 20] . In agreement to these findings, our study demonst rated that the TRPA1 antagonism either before or after urinary bladder cystitis developmen t efficiently decreased the number and the amplitude of non-voiding contraction s. This suggests that urothelium actively contributes to bladder contractil e response mediated by TRPA1. Previous studies have reported the role of TRPA1 in bladder overactivity ; for instance, the TRPA1 agonists allyl isothiocyan ate, sodium sulphide or cinnamaldehyde increase the micturition frequency, and decrease voiding volume and intercontration interval [15, 20, 62] . In addition, both the antagonism by HC 030031 and the down-regul ation by anti-sense oligonucleotid e of TRPA1 significantly reduced the number and amplitude of non-voiding contractions in bladder overactivity induced by spinal cord injury [17] .
It is noteworthy to mention that the dysfunction of the external urethal sphincter triggers the developmen t of detrusor-sphi ncter dyssynergia. In our study, we observed marked alterations in voiding caused by the external urethral sphincter dysfunction such as reduced voided volume and voiding efficiency and greater urinary bladder capacity. These events were only partially recovered by TRPA1 antagoni sm. The lack of effectiveness of HC 030031 could be explained by a restriction in TRPA1 function, i.e., the receptor does not seem to exert any descending control of spinal motor neurons that regulate external urethral sphincter. However , TRPA1 has a significant role in to regulate the activity of the urothelium.
Conclusion
In summary, our findings demonst rate that treatment with cyclophospham ide induces haemorr hagic cystitis with evident abdominal discomfort. The urinary bladder overactivi ty and the reduction in the nociceptive threshold were depende nt on the activation of TRPA1. As mentioned previously, the cyclopho sphamide metabolite, acrolein might be the main agent responsible for TRPA1-dependen t urinary bladder dysfunction. Therefore, antagonism of TRPA1 may be a strategy to countera ct the urotoxic side effects of some chemothera peutic drugs.
